Breaking News

AstraZeneca Invests $300M in MD Facility

Will create more than 150 new highly skilled jobs to focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world.

Author Image

By: Charlie Sternberg

Associate Editor

AstraZeneca is investing $300 million in a facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply.   More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas.   The site represents the latest investment in cell therapy for Astra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters